BR112021006388A2 - composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero - Google Patents

composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero

Info

Publication number
BR112021006388A2
BR112021006388A2 BR112021006388A BR112021006388A BR112021006388A2 BR 112021006388 A2 BR112021006388 A2 BR 112021006388A2 BR 112021006388 A BR112021006388 A BR 112021006388A BR 112021006388 A BR112021006388 A BR 112021006388A BR 112021006388 A2 BR112021006388 A2 BR 112021006388A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
mammal
treating
viral infection
Prior art date
Application number
BR112021006388A
Other languages
English (en)
Inventor
Westman Jacob
Original Assignee
Curovir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curovir Ab filed Critical Curovir Ab
Publication of BR112021006388A2 publication Critical patent/BR112021006388A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto,composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero. o composto é útil em terapia, em particular como um agente antiviral, por exemplo, no tratamento de uma infecção viral por rna. uma composição farmacêutica que compreende o composto.
BR112021006388A 2018-10-10 2019-08-20 composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero BR112021006388A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18199486 2018-10-10
PCT/EP2019/072220 WO2020074159A1 (en) 2018-10-10 2019-08-20 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections

Publications (1)

Publication Number Publication Date
BR112021006388A2 true BR112021006388A2 (pt) 2021-07-06

Family

ID=63832264

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006388A BR112021006388A2 (pt) 2018-10-10 2019-08-20 composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero

Country Status (15)

Country Link
US (1) US20210340147A1 (pt)
EP (1) EP3864017B1 (pt)
JP (1) JP7397072B2 (pt)
KR (1) KR20210074312A (pt)
CN (1) CN112969703A (pt)
AU (1) AU2019359166B2 (pt)
BR (1) BR112021006388A2 (pt)
CA (1) CA3115128A1 (pt)
ES (1) ES2960698T3 (pt)
IL (1) IL281956B2 (pt)
MX (1) MX2021003915A (pt)
PL (1) PL3864017T3 (pt)
SG (1) SG11202103496VA (pt)
WO (1) WO2020074159A1 (pt)
ZA (1) ZA202102974B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021032611A1 (en) 2019-08-20 2021-02-25 Curovir Ab Heteroaromatic compounds useful in therapy
WO2024184442A1 (en) 2023-03-09 2024-09-12 Curovir Ab Compound and formulation for systemic therapy by oral transmucosal administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
US8633198B1 (en) * 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
EP3096762B1 (en) 2014-01-22 2023-06-28 Curovir Ab Pyrazolo[1,5-a]pyrimidines as antiviral compounds
WO2016091774A1 (en) * 2014-12-08 2016-06-16 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
CN107949563B (zh) * 2015-06-24 2020-06-05 库洛维公司 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
ES2880327T3 (es) 2017-04-05 2021-11-24 Curovir Ab Compuestos heteroaromáticos útiles en terapia

Also Published As

Publication number Publication date
JP2022504082A (ja) 2022-01-13
IL281956A (en) 2021-05-31
AU2019359166B2 (en) 2024-07-11
AU2019359166A1 (en) 2021-05-27
CN112969703A (zh) 2021-06-15
EP3864017A1 (en) 2021-08-18
ES2960698T3 (es) 2024-03-06
KR20210074312A (ko) 2021-06-21
SG11202103496VA (en) 2021-05-28
EP3864017B1 (en) 2023-07-26
IL281956B2 (en) 2024-07-01
WO2020074159A1 (en) 2020-04-16
JP7397072B2 (ja) 2023-12-12
CA3115128A1 (en) 2020-04-16
ZA202102974B (en) 2023-10-25
EP3864017C0 (en) 2023-07-26
IL281956B1 (en) 2024-03-01
MX2021003915A (es) 2021-06-04
PL3864017T3 (pl) 2024-02-19
US20210340147A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
BR112018071585A2 (pt) formulações de um inibidor de lsd1
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112019004496A2 (pt) estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CO2022000481A2 (es) Inhibidores de enzimas
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
CL2016000300A1 (es) Métodos terapéuticos